Pomegranate juice may soothe gut inflammation in colitis patients
NCT ID NCT07115862
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study is testing whether drinking 8 ounces of pomegranate juice daily for 8 weeks can reduce gut inflammation and improve quality of life in people with mild-to-moderate ulcerative colitis. Researchers will also look at how the juice affects gut bacteria. The study involves 30 adults who follow a low-fiber diet and will compare the juice period to a no-juice period.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- pomegranate juice
- What this could lead to
- If it works, this could point toward a simple dietary supplement to help manage ulcerative colitis symptoms and reduce inflammation.
- What could go wrong
- This is a very small pilot study with only 30 participants, so results may not apply to everyone. It also relies on self-reported symptoms and may not show clear benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * • Adults ≥ 18 yo * Following a low-polyphenol and fiber diet (\< 3 servings of fruits/vegetables per day) * Mild-to-moderate UC at the time of screening (2 ≤ partial Mayo scores ≤ 5) * Supportive evidence of active inflammation (hsCRP \>1 mg/L, fecal calprotectin \>50 µg/g stool, or abnormal lower endoscopy) in individuals with biopsy-proven UC * Patients on 5-aminosalicylates must be on a stable dose for ≥ 4 weeks prior to screening * Patients on treatment with immunosuppressive therapy (e.g., azathioprine/6-mercaptopurine, methotrexate) must be on stable dose for 8 weeks prior to baseline visit * At the time of baseline visit, patients may be on no more than 20 mg/day of prednisone and 9 mg/day of budesonide MMX * Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent. Exclusion Criteria: * • Non-English speaker * Vegetarian/vegan * Known pomegranate allergy * Documented chronic disease besides UC, including diabetes, renal or liver diseases, metabolic syndrome, active cancer, MI or stroke, history of gastric bypass * Patients with CD, indeterminate/severe to fulminant colitis * History of colectomy or colonic dysplasia * Presence of ileal pouch or ostomy * Evidence of active bacterial or viral gastroenteritis as indicated by positive stool studies for ova \& parasites, Clostridium difficile, and stool culture * Recent hospitalizations (within 2 weeks of screening) for UC requiring IV steroids * Presence of the following labs indicative of severe colitis: a. Hemoglobin \< 8.0 g/dl b. Albumin \< 3.0 g/dl * Recent systemic antibiotics use (within 3 months of screening) or active use of anti-diarrheal medications * Taking supplements known to affect metabolism or gut microbiota composition (probiotics, fiber, etc.), unless willing to stop for the study duration * Use of Total Parenteral Nutrition (TPN) * Use of cyclosporine, tacrolimus, or thalidomide within 2 months prior to screening * Taking exogenous hormones (e.g., hormone replacement therapy) * Recent weight fluctuations (\>10% in the last 6 months) * Smoker or living with a smoker * Use of \>20 g of alcohol per day * Unable or unwilling to comply with the study protocol (including unwillingness to avoid watermelon and other lycopene-rich foods for the whole duration of the study) * Unable to provide consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ulcerative colitis (disorder) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UCLA Center for Human Nutrition
RECRUITINGLos Angeles, California, 90095, United States
-
West Los Angeles VA Medical Center
NOT_YET_RECRUITINGLos Angeles, California, 90073, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ancient wisdom meets AI: could TCM features sharpen colorectal screening?
- Can a mediterranean diet and Time-Restricted eating tame gut inflammation?
- Can a biologic drug calm the gut in ulcerative colitis? a Real-World trial seeks answers
- AI may predict ulcerative colitis severity before a scope — a study puts it to the test
- New oral drug for inflammatory bowel disease enters first human tests
- Could a yeast and butyrate mix keep UC in check?